AR080754A1 - Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 - Google Patents

Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10

Info

Publication number
AR080754A1
AR080754A1 ARP110100694A ARP110100694A AR080754A1 AR 080754 A1 AR080754 A1 AR 080754A1 AR P110100694 A ARP110100694 A AR P110100694A AR P110100694 A ARP110100694 A AR P110100694A AR 080754 A1 AR080754 A1 AR 080754A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkyloxy
group
hydrogen
substituted
Prior art date
Application number
ARP110100694A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR080754A1 publication Critical patent/AR080754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a nuevos derivados de imidazo[1,2-a]pirazina que son inhibidores de la enzima fosfodiesterasa 10 (PDE10) y que resultan utiles para el tratamiento o la prevencion de trastornos neurologicos, psiquiátricos y metabolicos en los cuales participa la enzima PDE10. También se dirige a composiciones farmacéuticas que comprenden dichos compuestos, a procesos para preparar dichos compuestos y composiciones, y al uso de dichos compuestos o composiciones farmacéuticas para la prevencion o el tratamiento de trastornos y enfermedades neurologicas, psiquiátricas y metabolicas. Reivindicacion 1: Un compuesto de formula (1) o una forma estereoisomérica de dicho compuesto, en donde R1 se selecciona del grupo que consiste en un radical de formula (a-1), (a-2) y (a-3); en donde cada R6, R7, R8 se selecciona independientemente del grupo que consiste en fluoro; alquilo C1-4, alquiloxi C1-4 y alquilo C1-4 sustituido con 1, 2 o 3 átomos de fluoro; R9 es hidrogeno o alquilo C1-4; cada m1, m2 y m3 se selecciona independientemente de 0, 1, 2, 3 y 4; p2 se selecciona de 1, 2, 3 y 4; cada p1 Y p3 se selecciona independientemente de 1 y 2; o R1 se selecciona del grupo que consiste en piridinilo no sustituido; piridinilo sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste en halogeno, alquilo C1-4, trifluorometilo y alquiloxi C1-4; y tetrahidropiranilo no sustituido; R2 se selecciona del grupo que consiste en hidrogeno; alquilo C1-4, trifluorometilo; cicloalquilo C3-8, alquiloxi C1-4 y ciano; R3 se selecciona del grupo que consiste en hidrogeno; alquilo C1-4, cicloalquilo C3-8 y alquilo C1-4 sustituido con 1, 2 o 3 átomos de fluoro; Het es un anillo heterocíclico de 5 o 6 miembros, seleccionado del grupo que consiste en piridinilo; pirimidinilo; piridazinilo; pirazinilo; pirrolilo; oxazolilo; tiazolilo; imidazolilo; pirazolilo; isotiazolilo; isoxazolilo; oxadiazolilo y triazolilo; R4 se selecciona del grupo que consiste en hidrogeno; alquilo C1-4, alquilo C1-4 sustituido con 1, 2 o 3 átomos de fluoro; (difluorociclopropil)metilo; (ciclopropil)difluorometilo; hidroxialquilo C1-4, cicloalquilo C3-8, cicloalquil C3-8- aIquilo C1-4, alquiloxi C1-4-alquilo C1-6, alquiloxi C1-4, alquiloxi C1-4 sustituido con 1, 2 o 3 átomos de fluoro; cicloalquil C3-8-alquiloxi C1-4, alquiloxi C1-4-alquil C1-4-oxi; alquil C1-4-carbonilo; alquil C1-4-carbonilalquilo C1-4, cicloalquil C3-8-carbonilo; cicloalquil C3-8-carbonilalquilo C1-4, fenilo no sustituido; fenilo sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste en halogeno, alquilo C1-4, trifluorometilo, trifluorometoxi, ciano y alquiloxi C1-4; bencilo no sustituido; bencilo sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste en halogeno, alquilo C1-4, trifluorometilo, trifluorometoxi, ciano y alquiloxi C1-4, tetrahidrofuranilo no sustituido; tetrahidrofuranilmetilo; tetrahidropiranilo no sustituido; tetrahidropiranilmetilo; piridinilmetilo; quinolinilmetilo; (NR10R11)alquilo C1-4 y NR10R11; R5 es hidrogeno o fluoro; R10 y R11 se seleccionan independientemente de hidrogeno y alquilo C1-4, o 5 tomados junto con el átomo de nitrogeno anular pueden formar un radical de formula (b-1), (b-2) o (b-3) en donde cada R12, R13 y R14 es independientemente alquilo C1-4 o alquiloxi C1-4; R15 es hidrogeno o alquilo C1-4; cada q1, q2 y q3 se selecciona independientemente de 0, 1, 2, 3 y 4; s1 se selecciona de 1, 2, 3 y 4; cada s2 y s3 se selecciona independientemente de 1 y 2; o una sal o solvato farmacéuticamente aceptable de dicho compuesto.
ARP110100694A 2010-03-09 2011-03-04 Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 AR080754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10155981 2010-03-09

Publications (1)

Publication Number Publication Date
AR080754A1 true AR080754A1 (es) 2012-05-09

Family

ID=42536437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100694A AR080754A1 (es) 2010-03-09 2011-03-04 Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10

Country Status (22)

Country Link
US (1) US8859543B2 (es)
EP (1) EP2545055B1 (es)
JP (1) JP5746719B2 (es)
KR (1) KR101332585B1 (es)
CN (1) CN102791713B (es)
AR (1) AR080754A1 (es)
AU (1) AU2011226174B2 (es)
BR (1) BR112012022650B1 (es)
CA (1) CA2790571C (es)
CL (1) CL2012002487A1 (es)
CO (1) CO6602133A2 (es)
EA (1) EA022012B1 (es)
ES (1) ES2646827T3 (es)
MX (1) MX2012010391A (es)
MY (1) MY160305A (es)
NZ (1) NZ601931A (es)
PH (1) PH12012501749A1 (es)
SG (1) SG183524A1 (es)
TW (1) TWI504601B (es)
UA (1) UA107952C2 (es)
WO (1) WO2011110545A1 (es)
ZA (1) ZA201206715B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051342A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP2014510055A (ja) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体
US8592423B2 (en) * 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
CA2838645C (en) 2011-06-27 2020-03-10 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
TN2015000490A1 (fr) * 2013-05-02 2017-04-06 Pfizer Dérivés d'imidazo-triazine servant d' inhibiteurs de pde10
US9249163B2 (en) 2013-06-11 2016-02-02 Janssen Pharmaceutica Nv. PDE10a inhibitors for the treatment of type II diabetes
US9193736B2 (en) 2013-06-11 2015-11-24 Janssen Pharmaceutica, Nv PDE 10a inhibitors for the treatment of type II diabetes
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
MX375485B (es) * 2016-06-16 2025-03-06 Janssen Pharmaceutica Nv Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta
WO2018045276A1 (en) 2016-09-02 2018-03-08 Ironwood Pharmaceuticals, Inc. Fused bicyclic sgc stimulators
BR112019020309A2 (pt) 2017-03-29 2020-04-28 Janssen Pharmaceutica Nv derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta
RS62818B1 (sr) 2017-10-18 2022-02-28 Incyte Corp Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma
CR20250050A (es) * 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN110845426A (zh) * 2019-11-29 2020-02-28 都创(上海)医药科技有限公司 一种2-氯-5-氰基嘧啶化合物制备方法
CN114989177B (zh) * 2022-07-11 2023-01-24 江西瑞威尔生物科技有限公司 一种咪唑并吡嗪类化合物的制备工艺

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242513A (en) 1979-03-05 1980-12-30 Appleton Papers Inc. Lactone compounds containing a heterocyclic radical
US4507294A (en) 1982-03-08 1985-03-26 Schering Corp. Imidazo[1,2-a]pyrazines
US4376772A (en) 1981-12-09 1983-03-15 Merck & Co., Inc. Use of piperazinyl-imidazo[1,2-a]pyrazines in sedation
EP0226641B1 (en) 1985-05-25 1989-10-18 Yoshitomi Pharmaceutical Industries, Ltd. Oxodiazine compounds
AU5921890A (en) 1989-06-13 1991-01-08 Smithkline Beecham Corporation Monokine activity interference
KR920702621A (ko) 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
KR910011852A (ko) 1989-12-04 1991-08-07 폴 디. 매튜카이티스 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물
EP0533837A4 (en) 1990-06-12 1994-11-17 Smithkline Beecham Corp Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
JPH06503349A (ja) 1990-12-13 1994-04-14 スミスクライン・ビーチャム・コーポレイション 新規ｃｓａｉｄｓ
AU9137591A (en) 1990-12-13 1992-07-08 Smithkline Beecham Corporation Novel csaids
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
WO1996034866A1 (en) 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
WO1998035967A2 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
JP2001514260A (ja) 1997-09-02 2001-09-11 デュポン ファーマシューティカルズ カンパニー Ｃｎｓおよびストレス関連疾患の治療に有用な、副腎皮質刺激ホルモン放出ホルモン拮抗剤としての、複素環基が置換した環縮合ピリジン類およびピリミジン類
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
KR20030016222A (ko) 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6589952B2 (en) 2000-07-14 2003-07-08 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
WO2002034748A1 (fr) 2000-10-24 2002-05-02 Sankyo Company, Limited Derives d'imidazopyridine
EP1343785A2 (de) 2000-12-13 2003-09-17 Basf Aktiengesellschaft Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
DE60204674T2 (de) 2001-03-14 2006-05-18 Eli Lilly And Co., Indianapolis Retinoid x rezeptormodulatoren
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
JP2004536807A (ja) 2001-05-30 2004-12-09 アルテオン インコーポレイテッド 緑内障ｖの治療方法
WO2002096363A2 (en) 2001-05-30 2002-12-05 Alteon, Inc. Method for treating fibrotic diseases or other indications
PL366827A1 (en) 2001-06-21 2005-02-07 Smithkline Beecham Corporation Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
DE60211539T2 (de) 2001-10-05 2006-09-21 Smithkline Beecham Corp. Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
US20050079176A1 (en) 2002-01-22 2005-04-14 Pierson Iii Richard N. Treating stress response with chemokine receptor ccr5 modulators
DK1483265T3 (da) 2002-03-05 2007-03-19 Lilly Co Eli Purinderivater som kinaseinhibitorer
CN100537571C (zh) * 2002-04-19 2009-09-09 细胞基因组公司 咪唑并[1,2-а]吡嗪-8-基胺,其制备方法及使用方法
JP2003313126A (ja) 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
WO2003097062A1 (en) 2002-05-13 2003-11-27 Merck & Co., Inc. Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
US20040014957A1 (en) 2002-05-24 2004-01-22 Anne Eldrup Oligonucleotides having modified nucleoside units
US20050245520A1 (en) 2002-07-31 2005-11-03 Nerina Dodic 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors
GB0217783D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
AU2003256297A1 (en) 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US7312341B2 (en) 2002-09-09 2007-12-25 Cgi Pharmaceuticals, Inc. 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
EP1539749A4 (en) 2002-09-13 2007-06-13 Merck & Co Inc BY CONDENSED HETEROBICYCLOGRUPPEN SUBSTITUTED PHENYL COMPOUNDS AS METOBOTROPE GLUTAMATE-5 MODULATORS
MXPA05003058A (es) 2002-09-19 2005-05-27 Schering Corp Nuevas imidazopiridinas como inhibidores de cinasa dependientes de ciclina.
EP1543008B1 (en) 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
NZ538686A (en) 2002-09-23 2008-01-31 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
AU2003271185A1 (en) 2002-10-15 2004-05-04 Takeda Pharmaceutical Company Limited Imidazopyridine derivative, process for producing the same, and use
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
EP1582516B1 (en) 2003-01-10 2013-07-17 Idemitsu Kosan Co., Ltd. Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7329668B2 (en) 2003-02-25 2008-02-12 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US7041671B2 (en) 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US20060100235A1 (en) 2003-04-11 2006-05-11 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
WO2004103991A1 (en) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. 2-substituted piperidines, focused library and a pharmaceutical compound
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
BRPI0412689A (pt) 2003-07-14 2006-10-03 Arena Pharm Inc derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
KR100553752B1 (ko) 2003-10-13 2006-02-20 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
RU2405784C2 (ru) * 2003-10-15 2010-12-10 Оси Фармасьютикалз, Инк. Имидазопиразины в качестве ингибиторов тирозинкиназ
EP1682549B1 (en) 2003-10-28 2010-09-22 Sepracor Inc. Imidazo[1,2-a]pyridine anxiolytics
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
WO2005080355A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
ATE424208T1 (de) 2004-06-09 2009-03-15 Oncalis Ag Proteinkinaseinhibitoren
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
WO2006025567A1 (ja) 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. 新規置換イミダゾール誘導体
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
CN101083996A (zh) 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
CA2586259A1 (en) 2004-11-08 2006-05-11 Banyu Pharmaceutical Co., Ltd. Novel fused imidazole derivative
CA2587192A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
EP1838312A4 (en) 2004-12-17 2010-01-20 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP1832588A4 (en) 2004-12-28 2009-09-02 Takeda Pharmaceutical CONDENSED IMIDAZOLE COMPOUND AND ITS USE
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
JP4971300B2 (ja) 2005-03-21 2012-07-11 イーライ リリー アンド カンパニー イミダゾピリダジン化合物
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
PE20061110A1 (es) 2005-03-24 2006-10-20 Glaxo Group Ltd Derivados de imidazopiridina como antagonistas de la bomba de acido (apa)
WO2006107784A1 (en) 2005-04-05 2006-10-12 Eli Lilly And Company Imidazopyridazine compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
GB0513423D0 (en) 2005-06-30 2005-08-03 Glaxo Group Ltd Novel compounds
WO2007006533A2 (en) 2005-07-11 2007-01-18 Novartis Ag Indolylmaleimide derivatives
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US20070185063A1 (en) 2005-08-23 2007-08-09 Idenix Pharmaceuticals, Inc. Seven-membered ring nucleosides
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
TW200800213A (en) 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
CN101291582A (zh) * 2005-09-02 2008-10-22 艾博特公司 以咪唑为基础的新杂环化合物
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
KR101121292B1 (ko) 2005-09-27 2012-04-13 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ2 길항제로서 옥사다이아졸일 피라졸로-피리미딘
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
KR20080074963A (ko) 2005-11-10 2008-08-13 쉐링 코포레이션 단백질 키나제 억제제로서의 이미다조피라진
WO2007056468A1 (en) 2005-11-10 2007-05-18 Schering Corporation Methods for inhibiting protein kinases
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
EP1984375A2 (en) 2006-01-25 2008-10-29 Smithkline Beecham Corporation Chemical compounds
JP2009528388A (ja) 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害物質として用いられるチアゾロン
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
MX2008015747A (es) 2006-06-06 2008-12-19 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa.
ITVA20060041A1 (it) 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
WO2008011560A2 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
WO2008014219A2 (en) 2006-07-24 2008-01-31 Smithkline Beecham Corporation Thiozolidinedione derivatives as p13 kinase inhibitors
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
US20100144743A1 (en) 2006-09-05 2010-06-10 Board Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
AU2007338601C1 (en) 2006-09-05 2014-07-24 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
US7790741B2 (en) 2006-10-06 2010-09-07 Abbott Laboratories Imidazothiazoles and imidazoxazoles
CA2612656A1 (en) 2006-10-30 2008-04-30 Draxis Specialty Pharmaceuticals Inc. Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(i) tetrafluoroborate
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
CN101589045A (zh) 2006-11-08 2009-11-25 先灵公司 作为蛋白质激酶抑制剂的咪唑并吡嗪
WO2008063669A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
US7622584B2 (en) 2006-11-24 2009-11-24 Samsung Mobile Display Co., Ltd. Imidazopyridine-based compound and organic light emitting diode including organic layer comprising the imidazopyridine-based compound
CA2670870A1 (en) 2006-12-04 2008-06-12 Astrazeneca Ab Antibacterial polycyclic urea compounds
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
US8138197B2 (en) 2007-01-12 2012-03-20 Msd K.K. Spirochromanon derivatives
US20080242862A1 (en) 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
WO2008121687A2 (en) 2007-03-28 2008-10-09 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
RU2467008C2 (ru) 2007-04-03 2012-11-20 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ
UA99610C2 (en) 2007-04-10 2012-09-10 Х. Луннбэк А/С Heteroaryl amide analogues as p2x7 antagonists
WO2008133192A1 (ja) 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
EA200901488A1 (ru) 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
PL2155758T3 (pl) 2007-05-10 2013-06-28 Biocryst Pharm Inc Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka
US20100216779A1 (en) 2007-06-01 2010-08-26 Glaxosmithkline Llc Imidazopyridine Kinase Inhibitors
WO2008156614A2 (en) 2007-06-14 2008-12-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
KR101030007B1 (ko) 2007-06-15 2011-04-20 삼성모바일디스플레이주식회사 헤테로방향환 함유 화합물, 이의 제조 방법 및 이를 이용한유기 발광 소자
EP2170882A1 (en) 2007-06-26 2010-04-07 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CA2693817A1 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
CN101808666A (zh) 2007-07-31 2010-08-18 先灵公司 作为抗癌治疗的抗有丝分裂剂和激光激酶抑制剂组合
BRPI0814939A2 (pt) 2007-08-10 2015-01-27 Glaxosmithkline Llc Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
CL2008002397A1 (es) 2007-08-14 2009-09-25 Bayer Schering Pharma Ag Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna.
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
WO2009061856A1 (en) 2007-11-09 2009-05-14 The Salk Instituite For Biological Studies Non-nucleoside reverse transcriptase inhibitors
WO2009077334A1 (en) 2007-12-14 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
WO2009086123A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-a] pyridine compounds
TW200936545A (en) 2007-12-21 2009-09-01 Idemitsu Kosan Co Organic electroluminescent device
WO2009086130A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
WO2009097233A1 (en) 2008-01-28 2009-08-06 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP2257161B1 (en) 2008-02-26 2012-04-25 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
JP5637982B2 (ja) 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
DE102008017853A1 (de) 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
SI2268642T1 (sl) 2008-04-23 2015-05-29 Gilead Sciences, Inc. 1'-substituirani karba-nukleozidni analogi za antivirusno zdravljenje
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
JP5774982B2 (ja) 2008-05-19 2015-09-09 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． イミダゾ［１，２−ａ］ピリジン化合物
KR20110019385A (ko) * 2008-05-29 2011-02-25 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 이미다조피리딘 및 관련 유사체
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
WO2010002985A1 (en) 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
JP2011529073A (ja) 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
FR2934994B1 (fr) 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5416944B2 (ja) 2008-10-23 2014-02-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010059838A2 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP5210187B2 (ja) 2009-01-22 2013-06-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8367222B2 (en) 2009-02-27 2013-02-05 Idemitsu Kosan Co., Ltd. Organic electroluminescent device
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
JP5528427B2 (ja) 2009-03-24 2014-06-25 出光興産株式会社 有機エレクトロルミネッセンス素子
CA2756759C (en) 2009-04-16 2017-11-07 Joaquin Pastor Fernandez Imidazopyrazines for use as kinase inhibitors
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
KR101732289B1 (ko) 2009-08-19 2017-05-02 이데미쓰 고산 가부시키가이샤 방향족 아민 유도체 및 그것을 이용한 유기 전기발광 소자
WO2011059099A1 (ja) 2009-11-16 2011-05-19 出光興産株式会社 芳香族アミン誘導体及びそれを用いた有機エレクトロルミネッセンス素子
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10

Also Published As

Publication number Publication date
NZ601931A (en) 2014-01-31
HK1176057A1 (zh) 2013-07-19
CN102791713A (zh) 2012-11-21
MX2012010391A (es) 2012-10-10
CO6602133A2 (es) 2013-01-18
EA201290878A1 (ru) 2013-03-29
UA107952C2 (uk) 2015-03-10
PH12012501749A1 (en) 2015-02-25
ZA201206715B (en) 2015-04-29
EP2545055A1 (en) 2013-01-16
MY160305A (en) 2017-02-28
KR20120125656A (ko) 2012-11-16
CA2790571A1 (en) 2011-09-15
CA2790571C (en) 2018-04-24
JP5746719B2 (ja) 2015-07-08
CL2012002487A1 (es) 2012-11-30
JP2013521320A (ja) 2013-06-10
CN102791713B (zh) 2016-02-03
US20120329792A1 (en) 2012-12-27
BR112012022650A2 (pt) 2016-10-25
BR112012022650B1 (pt) 2021-09-21
BR112012022650A8 (pt) 2017-11-14
TWI504601B (zh) 2015-10-21
US8859543B2 (en) 2014-10-14
EA022012B1 (ru) 2015-10-30
AU2011226174A1 (en) 2012-09-13
AU2011226174B2 (en) 2015-01-22
SG183524A1 (en) 2012-09-27
TW201200519A (en) 2012-01-01
EP2545055B1 (en) 2017-08-09
WO2011110545A1 (en) 2011-09-15
KR101332585B1 (ko) 2013-11-25
ES2646827T3 (es) 2017-12-18

Similar Documents

Publication Publication Date Title
AR080754A1 (es) Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
AR078841A1 (es) Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
AR121661A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
AR110026A1 (es) Inhibidores de pde2
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
NZ597533A (en) Apoptosis signal-regulating kinase inhibitors
AR081072A1 (es) Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia
AR071283A1 (es) Compuestos heterociclicos y usos de los mismos
RU2018140092A (ru) Новые пиразолпиримидиновые производные
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR060537A1 (es) 1,2,4-triazoles trisustituidos
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
AR091781A1 (es) Antagonistas del receptor de 5-ht3
HRP20160744T2 (hr) Heterocikličke tvari i njihova uporaba kao modulatora receptora tirozin kinaza tipa iii
AR075383A1 (es) Derivados de triazolo[4,3-b]piridazina
JP2016507551A5 (es)
AR065531A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas.
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona
NZ629795A (en) 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
MY161229A (en) Fused heterocyclic derivatives as s1p modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal